SEP 2025 Oncology Cartoons by Dr Kanhu Charan Patro

SEP 2025 Oncology Cartoons by Dr Kanhu Charan Patro

1. DR KANHU CHARAN PATRO M.D, D.N.B[RT], MBA, FICRO, FAROI, PDCR, CEPC www.slideshare.net/search/slideshow?searchfrom=header&q=oncology+cartoons www.facebook.com/oncologycartoons/photos_albums 114 th Volume/SEPTEMBER 2025 ONCOLOGY CRATOONS EDUCATIVE E-BOOK

2. EPIDEMIOLOGY AND MAIN SUBTYPES OF RCC. 16 th AUG 2025/RENAL Valentina Schiavon /CANCERS/2023

3. Molecular targets and relative drugs used for ccRCC 17 th AUG 2025/RENAL Valentina Schiavon /CANCERS/2023

4. FOLLOW UP PROTOCOL OF MULTIFOCAL RENAL MASS 18 th AUG 2025/RENAL Sebastià et al. Insights into Imaging (2020)

5. Bosniak cyst classification management algorithm 19 th AUG 2025/RENAL Sebastià et al. Insights into Imaging (2020)

6. TRADITIONAL AND ACTIVELY EXPLORED NEW TREATMENTS IN GBM 20 th AUG 2025/BRAIN XI CHEN/FRONTIERS IN ONCOLOGY/2024

7. ACTIVELY EXPLORED NEW TREATMENTS IN GBM 21 st AUG 2025/BRAIN XI CHEN/FRONTIERS IN ONCOLOGY/2024

8. Results of major clinical studies of PD-1/PD-L1 inhibitors for HGG. 22 nd AUG 2025/BRAIN XI CHEN/FRONTIERS IN ONCOLOGY/2024

9. Major clinical studies immune check point inhibitors in Glioblastoma 23 rd AUG 2025/BRAIN XI CHEN/FRONTIERS IN ONCOLOGY/2024

10. MAJOR CLINICAL STUDIES-VACCINES IN GLIOBLASTOMA 24 th AUG 2025/BRAIN XI CHEN/FRONTIERS IN ONCOLOGY/2024

11. VORASIDENIB- IDH INHIBITOR - INDIGO TRIAL IN IDH MUT. GLIOMA 25 th AUG 2025/BRAIN Vihang Nakhate / Current Neurology and Neuroscience Reports/2024 Feature Details Population Grade 2 IDH1/2-mutant , post‑ surgery , non enhancing.no CTRT >1 month to 5year,recurrent and residual Treatment Vorasidenib 40 mg once daily vs. placebo Median PFS 27.7 months ( vorasidenib ) vs. 11.1 months (placebo) Hazard Ratio (PFS) ~0.39 (61% risk reduction) Time to Next Treatment Significantly delayed (HR ~0.26) Safety Generally well tolerated; some ALT elevation FDA Approval Granted August 6, 2024

12. DECISION MAKING IN LOW GRADE GLIOMA (LGG) 26 th AUG 2025/BRAIN /and Nader Pouratian / Curr Neurol Neurosci Rep/2010

13. OLD SCORING SYSTEMS IN LOW GRADE GLIOMA (LGG) 27 th AUG 2025/BRAIN Nader Pouratian / Curr Neurol Neurosci Rep/2010 /and

14. TARGETED THERAPY IN LOW GRADE GLIOMA (LGG) 28 th AUG 2025/BRAIN Brandon Lucke-Wold /WJCO/2024

15. SURVIVAL IN GLIOMAS ACCORDING TO MOLECULAR LEVEL 29 th AUG 2025/BRAIN Anna Lerner/Clinical Medicine/2024

16. SURVEILLANCE IMAGING PROTOCOL FOR BRAIN TUMOURS - NICE GUIDELINES . 30 th AUG 2025/BRAIN Anna Lerner/Clinical Medicine/2024

17. Layered integrated diagnosis of Glioma 31 st AUG 2025/BRAIN Anna Lerner/Clinical Medicine/2024

18. RADIOTHERAPY + PCV REGIMEN IN LOW GRADE GLIOMA 1 st Sep 2025/TRIAL Maria Diaz/The Cancer Journal/2025

19. RADIOTHERAPY + PCV/TMZ IN LOW GRADE GLIOMA 2 nd Sep 2025/ TRIAL Maria Diaz/The Cancer Journal/2025

20. Management schematic for adult-type LGGs. 3 rd Sep 2025/ALGORITHM Maria Diaz/The Cancer Journal/2025

21. "SEOM‑GEINO clinical guidelines for grade 2 G liomas 4 th Sep 2025/BRAIN Clinical and Translational Oncology/2024

22. Spider PLOT , also known as a Radar Chart or Web Chart 5 th Sep 2025/BIOSTAT CHAT GPT A Spider Chart , also known as a Radar Chart or Web Chart , is a graphical method used to display multivariate data in a two-dimensional chart with multiple axes starting from the same point. When to Use a Spider Chart: To compare multiple variables for a single item. To compare multiple items (e.g., students, machines, plans) across the same variables. Useful in performance analysis, skill assessment, and strategic planning .

23. ENDOMETRIAL CARCINOMA- EEE GUIDELINE UPDATE 2025 6 th SEP 2025/ENDO Nicole Concin /LANCET/2025

24. ENDOMETRIAL CARCINOMA- EEE MOLECULAR UPDATE 2025 Nicole Concin /LANCET/2025 7 th SEP 2025/ENDO

25. ENDOMETRIAL CARCINOMA- EEE GUIDELINE 2025 RISK GROUP Nicole Concin /LANCET/2025 8 th SEP 2025/ENDO

26. ENDOMETRIAL CARCINOMA- EEE GUIDELINE UPDATE 2025 Risk Group Estimated Recurrence Risk Characteristics Adjuvant/Primary Therapy Low Risk <8% STAGE I /II POLEmut STAGE IA /IC MMRd STAGE IA /NSMP AND (Low Grade (G1–G2), ER+ve No adjuvant therapy Intermediate Risk 8–14% STAGE IB , MMRd STAGE IIC , MMRd ,LVSI- STAGE 1B,IIA NSMP ,Low Grade ( G1–G2, ) ER+ ve Vaginal brachytherapy ( VBT ); Observation for select patients <60 AGE Low Grade(G1,G2) ENDOMETROID High–Intermediate Risk 15–24% STAGE II A , MMRd STAGE IIB , MMRd STAGE IIC , MMRd with cervical stromal or substantial LVSI STAGE IIB,NSMP (Low grade(G1,G2), ER+ve EBRT preferred VBT in pN patients OBSERVATION pN O LVSI- Low Grade(G1,G2) High Risk ≥25% STAGE IA2- II NSMP ,High Grade (G3) or ER– ve , p53abn (EXCEPT 1C) STAGE III–IVA any molecular subtype except POLEmut Chemotherapy + EBRT ( Concurrent or Sequential ) Chemo ± VBT CT+IMMUNO + EBRT IN STAGE IIIm – IVAm MMRD Uncertain Risk Unclear Early IA1 or IC with p53abn or NSMP , High- Grade(G3) /ER– ve STAGE III–IVA POLEmut Individualized Usually no adjuvant therapy Advanced/Metastatic High FIGO STAGE IVB or IVC Unresectable Residual Recurrent disease Systemic therapy (Chemo ± Immunotherapy ) Palliative RT Nicole Concin /LANCET/2025 9 th SEP 2025/ENDO

27. ENDOMETRIAL CARCINOMA- EEE GUIDELINE UPDATE 2025 Co-occurrence of more than one molecular abnormality in endometrial cancer (also known as multiple-classifier tumors ). These are recognized in updated molecular classifications Prognostic hierarchy (as per ESGO/ESTRO/ESP 2021): POLE > MMR-d > NSMP > p53-abn When multiple classifiers are present, the most favorable marker dictates prognosis. Such tumors may require careful multidisciplinary interpretation . Nicole Concin /LANCET/2025 Combination Interpretation Prognostic Driver POLE- mut + MMR-d Both mutations present Prognosis driven by POLE (excellent outcome) POLE- mut + p53-abn Both present Prognosis driven by POLE MMR-d + p53-abn Seen in ~3–5% cases Prognosis driven by MMR-d (intermediate) POLE + MMR-d + p53-abn Rare triple classifier Still driven by POLE 10 th SEP 2025/ENDO

28. MOLECULAR CLASSIFICATION OF GLIOMA GOOGLE 11 th SEP 2025/ENDO

29. Radiological difference between low and high grade gliomas 12 th SEP 2025/BRAIN MATHEW WILLMAN/ EXPLORATION OF NEUROSCIENCE/2023

30. Reading a Box and Whisker Plot 13 th SEP 2025/STATS https://www.simplypsychology.org/boxplots.html In descriptive statistics, a box plot or boxplot (also known as a box and whisker plot) is a type of chart often used in explanatory data analysis. Box plots visually show the distribution of numerical data and skewness by displaying the data quartiles (or percentiles) and averages. Box plots show the five-number summary of a set of data: including the minimum score, first (lower) quartile, median, third (upper) quartile, and maximum score . Boxplots make it easy to compare multiple data groups (e.g., different populations or experimental conditions) by aligning the “boxes” next to each other, highlighting differences in medians, overall spread, or outlier prevalence. Comparison

31. WHAT IS ITSS GRADE IN SWI? 14 th SEP 2025/BRAIN Omer Aydin/Polish Journal of Rdaiology /2017 SWI refers to Susceptibility Weighted Imaging An MRI sequence particularly sensitive to: Blood products ( hemorrhage, microbleeds ), Calcifications, Venous vasculature, Iron deposition   Intratumoral Susceptibility Signal (ITSS) grade is a measure of the extent of blood breakdown products (like hemosiderin) within a tumor, visualized as dark (hypointense) areas on SWI.  Higher ITSS grades (e.g., 2 or 3) correlate with a greater likelihood of hemorrhage Higher ITSS grades (2-3) are also linked to glioblastomas and features like necrosis, microvascular proliferation, and CDKN2A/B homozygous deletions .  Lower ITSS grades (0-1) are more common in oligodendrogliomas and astrocytomas , especially those with IDH mutations and 1p/19q co-deletions.  SWI grades based on ITSS numbers. Right frontal tumor ( oligodendroglioma )-no ITSS in the tumor, SWI grade 0; Right frontal tumor ( oligodendroglioma )-one ITSS (arrow), SWI grade 1; Left frontoparietal tumor (astrocytoma)-more than five ITSS in the tumor (arrow), SWI grade 2 ; Left parietal tumor ( glioblastoma )-numerous ITSS in the tumor, SWI grade 3.

32. September is Childhood Cancer Awareness Month 15 th SEP 2025/PUBLIC CHAT GPT In September, let's be wise, Look for signs that meet the eyes. Cancer is rare , but don’t delay, Know the signs and lead the way . Unexplained fever every day, That never seems to go away. Bruises coming without a fall, Tiny dots or none at all . Lumps or swellings on the skin, Neck, chest, or deep within. Weight loss that has no cause, A tired child who always draws pause . Bone or joint pain through the night, Limping legs, not feeling right. Frequent infections, pale skin too, These little things could give a clue . Headaches with vomiting in the morn, Sudden changes—don’t ignore. White glow in the pupil’s light, Could be a sign, not just bright . Gold’s the ribbon that we wear, To show the world we truly care. Childhood cancer, rare but real, Early signs help wounds to heal .